Allergan settles with Zydus and Cadila over Delzicol: 4 things to know

Dublin, Ireland-based Allergan Pharmaceuticals settled litigation over its Delzicol prescription used to treat ulcerative colitis.

Here's what you should know.

1. Allegan settled with Pennington, N.J.-based Zydus Pharmaceuticals and Ahmedabad, India-based Cadila Healthcare.

2. If approved by the FDA, Zydus and Cadila could market generic versions of Delzicol in the United States beginning March 1, 2020.

3. No details regarding the statement were available.

4. Allergan's stocks opened at $190.40 on Dec. 2, 2016 and closed at $189.71. At noon on Dec. 5, 2016 the stock was up to $190.24.

More articles on gastroenterology/endoscopy news:
AGA Patient INFO Center integrates with gMed: 3 notes
Allergan's GI business grows by 8.2% in Q3 & more — 3 GI company key notes
Valeant, Takeda deal crumbles; Valeant to invest in Salix: 6 things to know 

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast